TY - JOUR
T1 - Nongastrointestinal mucosa-associated lymphoid tissue (MALT) lymphomas
T2 - Clinical and therapeutic features of 24 localized patients
AU - Zinzani, P. L.
AU - Magagnoli, M.
AU - Ascani, S.
AU - Ricci, P.
AU - Poletti, V.
AU - Gherlinzoni, F.
AU - Frezza, G.
AU - Bendandi, M.
AU - Stefanetti, C.
AU - Merla, E.
AU - Pileri, S.
AU - Tura, S.
PY - 1997/9
Y1 - 1997/9
N2 - Background: Peripheral B-cell lymphoma of the marginal zone (MALT, low- grade), presenting as localized, extranodal disease, usually affects the elderly. The gastrointestinal tract is the most frequently involved extranodal location, representing 70% of all MALT lymphomas. Recently, numerous other extranodal sites involved by MALT lymphomas have also been described. Patients and methods: From January 1990 to October 1995, 24 patients with untreated nongastrointestinal low-grade MALT lymphoma were submitted to treatments ranging from the local approach of radiotherapy and local α-interferon (α-IFN) administration to chemotherapy. The tumours were located in the lung (seven cases), conjunctiva (four cases), lachrymal gland and orbital soft tissue (four cases), salivary glands (three cases), skin (three cases), breast (two cases), and thyroid (one case). All patients had low-grade stage IE tumours. Results: Chemotherapy was administered in 11 patients (six with lung, three with salivary gland, one with breast, and one with thyroid locations); radiation therapy was employed in seven patients (three with lachrymal gland, three with skin, and one with breast locations); local α-IFN administration was administered in five patients (four with conjunctival, and one with lachrymal gland sites); and surgery was employed in one patient with a lung tumour. All patients achieved complete remissions; three local recurrences and two relapses in other sites were observed. The global five-year survival rate was 100% with a relapse-free survival rate of 79%. Conclusions: These data confirm the significant efficacy of different therapeutic approaches to specific sites inbes obtaining a good remission rate for nongastrointestinal localized low-grade MALT lymphomas.
AB - Background: Peripheral B-cell lymphoma of the marginal zone (MALT, low- grade), presenting as localized, extranodal disease, usually affects the elderly. The gastrointestinal tract is the most frequently involved extranodal location, representing 70% of all MALT lymphomas. Recently, numerous other extranodal sites involved by MALT lymphomas have also been described. Patients and methods: From January 1990 to October 1995, 24 patients with untreated nongastrointestinal low-grade MALT lymphoma were submitted to treatments ranging from the local approach of radiotherapy and local α-interferon (α-IFN) administration to chemotherapy. The tumours were located in the lung (seven cases), conjunctiva (four cases), lachrymal gland and orbital soft tissue (four cases), salivary glands (three cases), skin (three cases), breast (two cases), and thyroid (one case). All patients had low-grade stage IE tumours. Results: Chemotherapy was administered in 11 patients (six with lung, three with salivary gland, one with breast, and one with thyroid locations); radiation therapy was employed in seven patients (three with lachrymal gland, three with skin, and one with breast locations); local α-IFN administration was administered in five patients (four with conjunctival, and one with lachrymal gland sites); and surgery was employed in one patient with a lung tumour. All patients achieved complete remissions; three local recurrences and two relapses in other sites were observed. The global five-year survival rate was 100% with a relapse-free survival rate of 79%. Conclusions: These data confirm the significant efficacy of different therapeutic approaches to specific sites inbes obtaining a good remission rate for nongastrointestinal localized low-grade MALT lymphomas.
KW - α-Interferon
KW - Low-grade MALT lymphoma
KW - Non-gastrointestinal
KW - Radiotherapy
UR - http://www.scopus.com/inward/record.url?scp=9844263374&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=9844263374&partnerID=8YFLogxK
U2 - 10.1023/A:1008278725106
DO - 10.1023/A:1008278725106
M3 - Article
C2 - 9358939
AN - SCOPUS:9844263374
VL - 8
SP - 883
EP - 886
JO - Annals of Oncology
JF - Annals of Oncology
SN - 0923-7534
IS - 9
ER -